Notch is out

Learn more ↗

Industry top-down

Medical Devices

Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.

32 companiesMedian revenue YoY: +9.5%EPS beat rate: —

AI industry top-down

The medical device industry generally experienced robust sales growth. Many companies recorded double-digit sales growth rates, reflecting the industry's vitality. However, individual company performance varied, with some firms experiencing a decline in EPS despite strong sales growth. Notably, EPS growth rates exhibited significant disparities across companies, indicating a mixed picture regarding profitability. While overall sales growth was positive, profitability metrics varied distinctly across companies.

  • Most companies show robust revenue growth
  • Some companies record high revenue growth rates
  • Significant disparity in EPS growth rates across companies
Where companies diverge: Discrepancy between revenue growth and EPS growth · Polarization of revenue growth rates by company

AI synthesis of disclosed results and analyst research across these companies — not investment advice.

Companies — latest quarter

CompanyPeriodRevenueRev YoYEPSEPS YoYSurprise
ABTABBOTT LABORATORIESFY2026 Q1$11.16B+7.8%$0.61-19.7%—
MDTMedtronic plcFY2027 Q1$9.76B+13.7%$1.14+40.7%—
SYKSTRYKER CORPFY2026 Q2$6.59B+9.4%$3.30+44.1%—
BSXBOSTON SCIENTIFIC CORPFY2026 Q2$5.44B+7.5%$0.61+15.1%—
EWEdwards Lifesciences CorpFY2026 Q2$1.74B+13.6%$0.42-25.0%—
DXCMDEXCOM INCFY2026 Q2$1.31B+13.1%$0.64+42.2%—
GEHCGE HealthCare Technologies Inc.FY2026 Q1$5.13B+7.4%$0.85-30.9%—
STESTERIS plcFY2026 Q3$1.5B+9.2%$1.96+12.0%—
ZBHZIMMER BIOMET HOLDINGS, INC.FY2026 Q2$2.18B+4.8%$1.03+33.8%—
PENPenumbra IncFY2026 Q2$390.05M+14.9%$0.88-23.5%—
TXG10x Genomics, Inc.FY2026 Q2$151.04M-12.6%$-0.14——
BIOBIO-RAD LABORATORIES, INC.FY2026 Q2$651M-0.1%$13.85+18.7%—
GMEDGLOBUS MEDICAL INCFY2026 Q2$789.61M+5.9%$1.10-26.2%—
BRKRBRUKER CORPFY2026 Q2$838.5M+5.2%$-0.41——
BIO-BBIO-RAD LABORATORIES, INC.FY2026 Q2$651M-0.1%$13.85+18.7%—
PODDINSULET CORPFY2026 Q2$801.7M+23.5%$1.37——
MASIMASIMO CORPFY2026 Q1$372M+9.5%$-3.12——
GKOSGLAUKOS CorpFY2026 Q2$185.61M+49.5%$-0.31——
HAEHAEMONETICS CORPFY2027 Q1$339.38M+5.6%$0.72+2.9%—
ITGRInteger Holdings CorpFY2026 Q2$464.11M-2.6%$0.69-33.7%—
LIVNLivaNova PLCFY2026 Q2$390.59M+10.8%$1.93+286.0%—
IRTCiRhythm Holdings, Inc.FY2026 Q2$224.17M+20.1%$-0.01——
NEOGNEOGEN CORPFY2026 Q3$211.2M-4.4%$-0.08——
TMDXTransMedics Group, Inc.FY2026 Q2$189.95M+20.7%$0.41-55.4%—
AXGNAxogen, Inc.FY2026 Q2$69.73M+23.1%$-0.03——
BFLYButterfly Network, Inc.FY2026 Q2$32.61M+39.5%$-0.05——
UFPTUFP TECHNOLOGIES INCFY2026 Q2$173.96M—$2.68——
ALMRAlamar Biosciences, Inc.FY2026 Q2$29.43M—$-0.22——
INSPInspire Medical Systems, Inc.FY2026 Q2$200.58M-7.6%$0.01——
ESTAESTABLISHMENT LABS HOLDINGS INC.FY2026 Q2$67.54M+31.7%$-0.39——
NVCRNovoCure LtdFY2026 Q2$183.58M+15.6%$-0.13——
214150CLASSYS Inc.FY2026 Q2₩105.52B+26.7%₩434.00+8.2%—

YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).

We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.